Germany is now the first country to launch the topical treatment for adults with moderate to severe CHE.

Omar Noor, MD, FAAD, hosted a live Case-Based Roundtable discussion with local dermatology clinicians to discuss 2 patients with plaque psoriasis and what would be the ideal topical treatment for each.

Share your insights, challenges, and clinical success stories while connecting with colleagues in a new Dermatology Times forum.

Investigators noted that further research is needed to monitor the prevalence of cardiovascular disease in patients with vitiligo.

Renata Block, PA-C, and Karan Lal, DO, discuss the critical role of advanced practice providers in dermatology, the power of mentorship, and how collaborative learning improves patient outcomes.

Hui addresses one of the NEA's Eczema Awareness Month weekly themes, "Eczema is more than the visuals."

Researchers behind the trial saw a decrease in the Severity of Alopecia Tool (SALT) score from 31 to 11.2 after 3 months of treatment with brevilin-A.

Researchers behind the study emphasized the urgent need to enhance the diagnostic skills of primary care practitioners to improve early detection of psoriasis.

In October's cover feature, Nicole A. Negbenebor, MD, FAAD, discusses the benefits of intralesional 5-fluorouracil injection for older patients with squamous cell carcinoma who may elect to delay therapy or are not ideal candidates for surgery.

Review insights from expert faculty as they look forward to the upcoming Elevate-Derm conference.

In case you missed it, we had news about benzene in benzoyl peroxide acne products tested at room temperature, the FDA's approved sNDA for 3 tubes of aminolevulinic acid hydrochloride, phase 2b trial data of zasocitinib, and more.

The novel drug demonstrated tolerability for AK treatment when applied to a field of 100 cm2 of the face or scalp.

Significant reductions in itch scores and improved assessments of PN severity and quality of life were observed throughout the study.

A recent review found clinical trials for HS lack diversity, limiting understanding of treatment efficacy for SOC populations.

Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.

Mease, the lead investigator on the trial, spoke about comparing varying mechanisms of action, primary and secondary endpoints, and how the results of BE BOLD could affect treatment choices.

Christopher Bunick, MD, PhD, reviews the latest findings on benzene in benzoyl peroxide, highlighting the importance of proper storage and patient safety.

The IL-17 inhibitor demonstrated biologic-level efficacy in moderate to severe plaque psoriasis.

AbbVie's Eczema Experience Pop-Up event recently provided attendees with immersive insights into the physical and psychosocial toll associated with eczema.

Experts shared pearls for acne and rosacea care at Maui Derm NP+PA Fall.

In this study, the highest infertility rate was seen in the patients living with hidradenitis suppurativa; however, no direct causality was seen for this, with the authors noting diseases and symptoms comprised the only factors with a statistically significant relationship to infertility.

A recent review found hair loss can severely impact self-esteem and body image, leading to social anxiety and emotional distress among affected youth.

In a Dermatology Times Case-Based Roundtable event, Andrew Alexis, MD, MPH, FAAD, reviewed 3 cases of patients with vitiligo treated with ruxolitinib cream.

Over 70% of patients achieved clear or minimal skin by week 48, with a 90% retention rate in diverse patients with PsO.

Christopher Bunick, MD, PhD, and Raj Chovatiya, MD, PhD, discuss results of an open-label phase 3b/4 study for atopic dermatitis.